CLC bio and Korilog Release KLAST Software Plug-in for Fast, Accurate Sequence Similarity Search in Next-Generation Sequencing
-- The combination of KLAST with CLC bio's market-leading bioinformatics platform accelerates sequence similarity search up to 25 times compared to current standard BLAST
-- CLC Genomics Workbench now comes with free issue of KLAST on four computer cores
AARHUS, Denmark, & QUESTEMBERT, France--(BUSINESS WIRE)--January 10, 2014--
CLC bio, a QIAGEN company (NASDAQ:QGEN)(FWB:QIA), today announced in collaboration with Korilog the release of the KLAST plug-in for CLC Genomics Workbench and CLC Main Workbench to accelerate the analysis of data from next-generation sequencing (NGS). KLAST is a new sequence similarity search tool which builds on a highly optimized implementation of the PLAST algorithm published in BMC Bioinformatics. KLAST is comparable to the current standard BLAST providing a similar accuracy, but can perform up to 25 times faster (with comparable search parameters and multicore threaded configuration). Another important KLAST benefit is that its algorithm is designed to compare two large sets of sequence databanks in a single run.
"The integration of the KLAST plug-in into CLC Genomics Workbench makes it possible to perform sequence similarity queries on very large data sizes, which adds significant utility to the very critical challenge in analyzing next-generation sequencing data," said Mikael Flensborg, Director of Global Partner Relations for CLC bio. "This solution will allow users to significantly accelerate their research by providing them with this fast, accurate, and NGS-scalable sequence similarity search software that integrates with our CLC Genomics Workbench, and offers a very user-friendly graphical interface."
"We are very enthusiastic to join forces with CLC bio's market-leading bioinformatics platform," said Patrick Durand, Founder and CEO of Korilog. "KLAST has been available for only a few months, and we have many researchers switching to use this new tool for their NGS applications. We're looking forward to offering more options for all of our users, as well as the users of both CLC Genomics Workbench and CLC Main Workbench."
The logic of KLAST is different from BLAST, and can provide significant accelerations of seed-based heuristic comparison methods using multi-threading and SSE instructions that make the tool high-performing and more scalable than BLAST on multiple cores.
January Bundle Campaign
Throughout January 2014, users purchasing a CLC Genomics Workbench license will receive the KLAST plug-in on four computer cores at no extra cost. For more information please visit: http://www.clcbio.com/link.php?id=631.
About KORILOG
Korilog, a privately held company based in Questembert, France, is a bioinformatics company providing the next generation of graphical software to integrate and explore data on pathways, genomes and proteomes. The company provides academic and industry research labs with desktop and web-based software programs (ngKLAST) as well as expert software development services to support researchers in their R&D activities. For further information, please visit http://www.korilog.com.
About CLC bio
CLC bio, a QIAGEN company based in Aarhus, Denmark, was founded in 2005 and has created the leading commercial data analysis solutions and workbenches for next-generation sequencing (NGS). It serves leading research institutions and top pharmaceutical companies worldwide. CLC bio's products are used as an integrating workbench to handle biological data generated by a sequencer through a series of analysis stages. CLC bio's leading products are CLC Genomics Workbench, a comprehensive and user-friendly analysis package for analyzing, comparing and visualizing NGS data; and CLC Genomics Server, a flexible enterprise-level infrastructure and analysis backbone for NGS data analysis. For more information, please visit http://www.clcbio.com.
About QIAGEN
QIAGEN N.V. is a Netherlands holding company publicly traded on NASDAQ and Frankfurt Prime Standard. The Company is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular insights. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2013, QIAGEN employed more than 4,100 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
CONTACT: CLC bio:
Lasse Görlitz, VP of Communications
Tel: +1 (617) 765 0687
Email: [email protected]
or
Public Relations:
Dr. Thomas Theuringer
Director Public Relations
+49 2103 29 11826
+1 240 686 7425
Email: [email protected]
www.twitter.com/qiagen
www.qiagen.com/About-Us/Press-and-Media/
or
Investor Relations:
John Gilardi
VP Corporate and Investor Relations
+49 2103 29 11711
Email: [email protected]